Last updated: 04/01/2021 10:10:05
PRJ2311: Medullary Thyroid Carcinoma Surveillance Study: a Case-Series Registry
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Ongoing
Ongoing
Trial overview
Official title: PRJ2311: Medullary Thyroid Carcinoma Surveillance Study: a Case-Series Registry
Trial description: Medullary Thyroid Carcinoma Surveillance Study: A Case-Series Registry This study is conducted in the United States of America (USA). The aim of the study is to monitor the number of annual new cases of medullary thyroid carcinoma (MTC) and to establish a registry for these new cases in order to identify any possible increase after the introduction of liraglutide, exenatide once-weekly, albiglutide, and other GLP-1 receptor agonists into the US market.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Annual incidence of MTC in the US to identify any possible increase after the introduction of liraglutide, exenatide once-weekly, albiglutide and other GLP-1 receptor agonists into the US market
Timeframe: 15 years
Secondary outcomes:
Not applicable
Interventions:
Other: No treatment given
Enrollment:
1
Observational study model:
Case-Only
Primary completion date:
2029-31-12
Time perspective:
Prospective
Clinical publications:
Not applicable
Medical condition
Diabetes Mellitus
Product
albiglutide, exenatide, liraglutide
Collaborators
Not applicable
Study date(s)
October 2014 to December 2029
Type
Observational
Phase
Not applicable
Participation criteria
Sex
Female & Male
Age
Not applicable
Accepts healthy volunteers
none
- A record of medullary thyroid carcinoma (MTC) identified from the US state/regional population-based cancer registries
- N/A
Inclusion and exclusion criteria
Inclusion criteria:
- A record of medullary thyroid carcinoma (MTC) identified from the US state/regional population-based cancer registries
Exclusion criteria:
- N/A
Trial location(s)
No location data available.
Study documents
Protocol
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
No study documents available
Recruitment status
Ongoing
Actual primary completion date
Not applicable
Actual study completion date
Not applicable
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website